231 related articles for article (PubMed ID: 32022878)
21. Racial treatment trends in localized/regional prostate carcinoma: 1992-1999.
Underwood W; Jackson J; Wei JT; Dunn R; Baker E; Demonner S; Wood DP
Cancer; 2005 Feb; 103(3):538-45. PubMed ID: 15612083
[TBL] [Abstract][Full Text] [Related]
22. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): 10-year results from a randomised, phase 3, factorial trial.
Denham JW; Joseph D; Lamb DS; Spry NA; Duchesne G; Matthews J; Atkinson C; Tai KH; Christie D; Kenny L; Turner S; Gogna NK; Diamond T; Delahunt B; Oldmeadow C; Attia J; Steigler A
Lancet Oncol; 2019 Feb; 20(2):267-281. PubMed ID: 30579763
[TBL] [Abstract][Full Text] [Related]
23. Rates of primary and secondary treatments for patients on active surveillance for localized prostate cancer-A population-based cohort study.
Matta R; Hird AE; Dvorani E; Saskin R; Nason GJ; Kulkarni G; Kodama RT; Herschorn S; Nam RK
Cancer Med; 2020 Oct; 9(19):6946-6953. PubMed ID: 32757442
[TBL] [Abstract][Full Text] [Related]
24. Stereotactic body radiotherapy versus conventional/moderate fractionated radiation therapy with androgen deprivation therapy for unfavorable risk prostate cancer.
Patel SA; Switchenko JM; Fischer-Valuck B; Zhang C; Rose BS; Chen RC; Jani AB; Royce TJ
Radiat Oncol; 2020 Sep; 15(1):217. PubMed ID: 32933541
[TBL] [Abstract][Full Text] [Related]
25. Race/ethnicity and the intensity of medical monitoring under 'watchful waiting' for prostate cancer.
Shavers VL; Brown M; Klabunde CN; Potosky AL; Davis W; Moul J; Fahey A
Med Care; 2004 Mar; 42(3):239-50. PubMed ID: 15076823
[TBL] [Abstract][Full Text] [Related]
26. Association of Prostate-Specific Antigen Velocity With Clinical Progression Among African American and Non-Hispanic White Men Treated for Low-Risk Prostate Cancer With Active Surveillance.
Nelson TJ; Javier-DesLoges J; Deka R; Courtney PT; Nalawade V; Mell L; Murphy J; Parsons JK; Rose BS
JAMA Netw Open; 2021 May; 4(5):e219452. PubMed ID: 33999164
[TBL] [Abstract][Full Text] [Related]
27. Factors influencing prostate cancer treatment decisions for African American and white men.
Gordon BE; Basak R; Carpenter WR; Usinger D; Godley PA; Chen RC
Cancer; 2019 May; 125(10):1693-1700. PubMed ID: 30695113
[TBL] [Abstract][Full Text] [Related]
28. National sociodemographic disparities in the treatment of high-risk prostate cancer: Do academic cancer centers perform better than community cancer centers?
Mahal BA; Chen YW; Muralidhar V; Mahal AR; Choueiri TK; Hoffman KE; Hu JC; Sweeney CJ; Yu JB; Feng FY; Kim SP; Beard CJ; Martin NE; Trinh QD; Nguyen PL
Cancer; 2016 Nov; 122(21):3371-3377. PubMed ID: 27434225
[TBL] [Abstract][Full Text] [Related]
29. African-American Men with Low-Risk Prostate Cancer: Modern Treatment and Outcome Trends.
Obirieze AC; Moten A; Allen D; Ahaghotu CA
J Racial Ethn Health Disparities; 2015 Sep; 2(3):295-302. PubMed ID: 26863460
[TBL] [Abstract][Full Text] [Related]
30. Geographic Distribution of Racial Differences in Prostate Cancer Mortality.
Fletcher SA; Marchese M; Cole AP; Mahal BA; Friedlander DF; Krimphove M; Kilbridge KL; Lipsitz SR; Nguyen PL; Choueiri TK; Kibel AS; Trinh QD
JAMA Netw Open; 2020 Mar; 3(3):e201839. PubMed ID: 32232449
[TBL] [Abstract][Full Text] [Related]
31. Racial inequities in the quality of surgical care among Medicare beneficiaries with localized prostate cancer.
Nyame YA; Holt SK; Etzioni RD; Gore JL
Cancer; 2023 May; 129(9):1402-1410. PubMed ID: 36776124
[TBL] [Abstract][Full Text] [Related]
32. Getting back to equal: The influence of insurance status on racial disparities in the treatment of African American men with high-risk prostate cancer.
Mahal BA; Ziehr DR; Aizer AA; Hyatt AS; Sammon JD; Schmid M; Choueiri TK; Hu JC; Sweeney CJ; Beard CJ; D'Amico AV; Martin NE; Lathan C; Kim SP; Trinh QD; Nguyen PL
Urol Oncol; 2014 Nov; 32(8):1285-91. PubMed ID: 24846344
[TBL] [Abstract][Full Text] [Related]
33. Factors associated with initial treatment and survival for clinically localized prostate cancer: results from the CDC-NPCR Patterns of Care Study (PoC1).
Schymura MJ; Kahn AR; German RR; Hsieh MC; Cress RD; Finch JL; Fulton JP; Shen T; Stuckart E
BMC Cancer; 2010 Apr; 10():152. PubMed ID: 20403178
[TBL] [Abstract][Full Text] [Related]
34. Comparison of Response to Definitive Radiotherapy for Localized Prostate Cancer in Black and White Men: A Meta-analysis.
Ma TM; Romero T; Nickols NG; Rettig MB; Garraway IP; Roach M; Michalski JM; Pisansky TM; Lee WR; Jones CU; Rosenthal SA; Wang C; Hartman H; Nguyen PL; Feng FY; Boutros PC; Saigal C; Chamie K; Jackson WC; Morgan TM; Mehra R; Salami SS; Vince R; Schaeffer EM; Mahal BA; Dess RT; Steinberg ML; Elashoff D; Sandler HM; Spratt DE; Kishan AU
JAMA Netw Open; 2021 Dec; 4(12):e2139769. PubMed ID: 34964855
[TBL] [Abstract][Full Text] [Related]
35. Patient-Reported Outcomes Through 5 Years for Active Surveillance, Surgery, Brachytherapy, or External Beam Radiation With or Without Androgen Deprivation Therapy for Localized Prostate Cancer.
Hoffman KE; Penson DF; Zhao Z; Huang LC; Conwill R; Laviana AA; Joyce DD; Luckenbaugh AN; Goodman M; Hamilton AS; Wu XC; Paddock LE; Stroup A; Cooperberg MR; Hashibe M; O'Neil BB; Kaplan SH; Greenfield S; Koyama T; Barocas DA
JAMA; 2020 Jan; 323(2):149-163. PubMed ID: 31935027
[TBL] [Abstract][Full Text] [Related]
36. Stereotactic Radiotherapy and Androgen Deprivation Therapy for Localized Prostate Cancer: A Retrospective Mono-institutional Experience.
Magli A; Bonù ML; Tonetto F; Moretti E; DE Giorgi G; Spiazzi L; Trovò M; Tomasini D; Magrini SM; Triggiani L
In Vivo; 2022; 36(1):306-313. PubMed ID: 34972727
[TBL] [Abstract][Full Text] [Related]
37. Active Surveillance for Men with Intermediate Risk Prostate Cancer.
Agrawal V; Ma X; Hu JC; Barbieri CE; Nagar H
J Urol; 2021 Jan; 205(1):115-121. PubMed ID: 32658588
[TBL] [Abstract][Full Text] [Related]
38. Sociodemographic factors associated with prostatectomy utilization and concordance with the physician data query for prostate cancer (United States).
Morris CR; Snipes KP; Schlag R; Wright WE
Cancer Causes Control; 1999 Dec; 10(6):503-11. PubMed ID: 10616820
[TBL] [Abstract][Full Text] [Related]
39. Use of stereotactic body radiotherapy for prostate cancer in the United States from 2004 through 2012.
Baker BR; Basak R; Mohiuddin JJ; Chen RC
Cancer; 2016 Jul; 122(14):2234-41. PubMed ID: 27171855
[TBL] [Abstract][Full Text] [Related]
40. A population-based analysis of contemporary patterns of care in younger men (<60 years old) with localized prostate cancer.
Wong AT; Safdieh JJ; Rineer J; Weiner J; Schwartz D; Schreiber D
Int Urol Nephrol; 2015 Oct; 47(10):1629-34. PubMed ID: 26329748
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
